HomeIMCR • NASDAQ
add
Immunocore Holdings PLC - ADR
Previous close
$58.00
Day range
$56.10 - $58.94
Year range
$42.21 - $76.98
Market cap
2.85B USD
Avg Volume
408.39K
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 66.27M | 12.17% |
Operating expense | 28.58M | -51.51% |
Net income | -18.51M | 44.30% |
Net profit margin | -27.94 | 50.34% |
Earnings per share | -0.32 | 41.46% |
EBITDA | -16.40M | 44.51% |
Effective tax rate | 24.21% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 442.63M | 9.98% |
Total assets | 597.00M | 13.33% |
Total liabilities | 228.16M | 21.45% |
Total equity | 368.84M | — |
Shares outstanding | 49.82M | — |
Price to book | 7.82 | — |
Return on assets | -7.33% | — |
Return on capital | -9.53% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -18.51M | 44.30% |
Cash from operations | -11.73M | -9.19% |
Cash from investing | -11.10M | -446.78% |
Cash from financing | 13.63M | 123.40% |
Net change in cash | 137.68K | 100.27% |
Free cash flow | -8.29M | 1.93% |
About
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
Founded
2008
Website
Employees
497